Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients-Reference-Cited by-同舟云学术

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Faraj Alan¹,Svensson Robin J.¹,Diacon Andreas H.²³,Simonsson Ulrika S. H.¹

Affiliation:

1. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

2. TASK Applied Science, Cape Town, South Africa

3. Division of Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa

Abstract

Antituberculosis (anti-TB) drug development is dependent on informative trials to secure the development of new antibiotics and combination regimens. Clofazimine (CLO) and pyrazinamide (PZA) are important components of recommended standard multidrug treatments of TB. Paradoxically, in a phase IIa trial aiming to define the early bactericidal activity (EBA) of CLO and PZA monotherapy over the first 14 days of treatment, no significant drug effect was demonstrated for the two drugs using traditional statistical analysis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01905-19

Reference45 articles.

1. WHO. 2018. Tuberculosis 2018. WHO, Geneva, Switzerland.

2. WHO. 2017. Global tuberculosis report 2017. WHO, Geneva, Switzerland.

3. Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis

4. WHO. 2018. Treatment guidelines for multidrug- and rifampicin-resistant tuberculosis. WHO, Geneva, Switzerland. Accessed 16 January 2019.

5. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring in tuberculosis;European Journal of Clinical Pharmacology;2024-09-06

2. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis;Antimicrobial Agents and Chemotherapy;2024-01-10

3. Clofazimine pharmacokinetics in HIV‐infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics;CPT: Pharmacometrics & Systems Pharmacology;2024-01-02

4. Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development;Frontiers in Pharmacology;2023-04-13

5. Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development;Frontiers in Pharmacology;2023-03-14